-
Mashup Score: 8De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy? - 1 year(s) ago
Since more than two decades, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is considered the gold standard for patients with acute coronary syndrome (ACS) as well as for those with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) [1]. The more potent P2Y12 inhibitors prasugrel and ticagrelor have shown to reduce ischemic events at…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5
Prasugrel dose de-escalation compared with conventional therapy may reduce the risk of net clinical outcomes, mostly driven by a reduction in bleeding without an increase in ischemic events in patients with DM.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Time for a paradigm shift? Making the case for tailored selection of antiplatelet therapy - 1 year(s) ago
This editorial refers to ‘Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patient
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
Summary of our collaborative works (review articles and Meta-analysis) with L. Spadafora, D. Fischman, W. Ullah, M.Savage, M. Gulati, JP Costabel, M Zeitouni…
Source: YouTubeCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
AbstractAims. The aim of this study was to evaluate the efficacy and safety of prasugrel-dose de-escalation therapy in patients with diabetes mellitus (DM)-acut
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5
Background: The benefit of dual antiplatelet therapy (DAPT) for reducing ischemic events is greatest in the early period of acute coronary syndrome, and recent randomized controlled trials have inves
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4
AbstractAims. The relative safety and efficacy of de-escalation, extended duration (ED) (>12-months), and standard dual antiplatelet therapy for 12-months (D
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis - 3 year(s) ago
The next steps should include further tailoring strategies to reduce bleeding in individual patients, Usman Baber says.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4
AbstractAims. The aim of this study was to describe the use of antithrombotic therapy following a bleeding event among patients with myocardial infarction (MI),
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3
East Asians treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) generally experience more intense platelet inhibitory responses resulting in an increased risk of major bleeding. Whether a half-dose de-escalation strategy improves the net clinical benefit in Korean patients with acute coro …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
#DAPT #DeEscalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy? https://t.co/rwnRPrVRYl